{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:57:27Z","timestamp":1782406647839,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.aprim.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T21:48:44Z","timestamp":1419976124000},"page":"505-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["An\u00e1lisis de coste-efectividad de dapagliflozina en comparaci\u00f3n con los inhibidores de la DPP4 y otros antidiab\u00e9ticos orales en el tratamiento de la diabetes mellitus tipo 2 en Espa\u00f1a"],"prefix":"10.1016","volume":"47","author":[{"given":"Eduardo Jos\u00e9","family":"Abad Paniagua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Casado Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Fern\u00e1ndez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Morales Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Beteg\u00f3n Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"S\u00e1nchez-Covisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Brosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2014.11.002_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.avdiab.2013.07.007","article-title":"Costes directos de la diabetes mellitus y de sus complicaciones en Espa\u00f1a. Estudio SECCAID","volume":"29","author":"Crespo","year":"2013","journal-title":"Av Diabetol."},{"key":"10.1016\/j.aprim.2014.11.002_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rce.2013.11.002","article-title":"Caracter\u00edsticas cl\u00ednicas y econ\u00f3micas asociadas a la diabetes tipo 2","volume":"214","author":"Sicras-Mainar","year":"2014","journal-title":"Rev Clin Esp."},{"key":"10.1016\/j.aprim.2014.11.002_bib0015","first-page":"202","article-title":"Recomendaciones para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo 2","volume":"43","author":"Men\u00e9ndez","year":"2011","journal-title":"Aten Primaria."},{"key":"10.1016\/j.aprim.2014.11.002_bib0020","unstructured":"Assessment report Forxiga\u00ae (dapagliflozina). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002322\/WC500136024.pdf"},{"key":"10.1016\/j.aprim.2014.11.002_bib0025","unstructured":"Ficha t\u00e9cnica dapagliflozina (Forxiga\u00ae). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002322\/WC500136026.pdf\/"},{"key":"10.1016\/j.aprim.2014.11.002_bib0030","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2014.11.002_bib0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Gac Sanit."},{"key":"10.1016\/j.aprim.2014.11.002_bib0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2010.01198.x","article-title":"A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes","volume":"12","author":"McEwan","year":"2010","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2014.11.002_bib0045","unstructured":"RedGDPS. Pr\u00e1ctica cl\u00ednica en la DM2. An\u00e1lisis cr\u00edtico de las evidencias por la redGDPS. 2010 [consultado 1 Dic 2013]. Disponible en: http:\/\/www.redgdps.org\/gestor\/upload\/file\/guias\/guia_gedaps_practica-cinica-2010.pdf"},{"key":"10.1016\/j.aprim.2014.11.002_bib0050","first-page":"25","article-title":"Hipoglucemiantes no insul\u00ednicos. Un segmento atomizado","volume":"26","author":"Divins","year":"2012","journal-title":"Farmacia Profesional."},{"key":"10.1016\/j.aprim.2014.11.002_bib0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/dom.12239","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis","volume":"16","author":"Goring","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2014.11.002_bib0060","unstructured":"Oxford Outcomes, Network Meta-Analysis of Anti-Diabetic Agents in Type 2 Diabetes Mellitus. Metformin add-on therapy (report and data on file). November 2011."},{"key":"10.1016\/j.aprim.2014.11.002_bib0065","unstructured":"Ficha t\u00e9cnica pioglitazona (Actos\u00ae). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000285\/WC500021386.pdf"},{"key":"10.1016\/j.aprim.2014.11.002_bib0070","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia."},{"key":"10.1016\/j.aprim.2014.11.002_bib0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues vs. NPH human insulin in type 2 diabetes. A meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.aprim.2014.11.002_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14360","article-title":"Newer agents for blood glucose control in type 2 diabetes: Systematic review and economic evaluation","volume":"14","author":"Waugh","year":"2010","journal-title":"Health Technol Assess."},{"key":"10.1016\/j.aprim.2014.11.002_bib0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1464-5491.2008.02483.x","article-title":"Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial","volume":"25","author":"Fajardo","year":"2008","journal-title":"Diabet Med."},{"key":"10.1016\/j.aprim.2014.11.002_bib0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making."},{"key":"10.1016\/j.aprim.2014.11.002_bib0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1524-4733.2005.00046.x","article-title":"The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects","volume":"8","author":"Currie","year":"2005","journal-title":"Value Health."},{"key":"10.1016\/j.aprim.2014.11.002_bib0100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/030079906X115757","article-title":"Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes","volume":"22","author":"Currie","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.aprim.2014.11.002_bib0105","first-page":"49","article-title":"Evaluation of suspected urinary tract infection in ambulatory women: A cost-utility analysis of office-based strategies","volume":"44","author":"Barry","year":"1997","journal-title":"J Fam Pract."},{"key":"10.1016\/j.aprim.2014.11.002_bib0110","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1185\/03007995.2014.899207","article-title":"The impact on utilities of differences in bodyweight among Canadian patients with type 2 diabetes","volume":"30","author":"Lane","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.aprim.2014.11.002_bib0115","unstructured":"Health Survey for England 2003 [consultado 1 Jul 2013]. Disponible en: http:\/\/www.dh.gov.uk\/PublicationsAndStatistics\/PublishedSurvey\/HealthSurveyForEngland\/HealthSurveyResults\/HealthSurveyResultsArticle\/fs\/en?CONTENT_ID=4098913&chk=4DPdlh"},{"key":"10.1016\/j.aprim.2014.11.002_bib0120","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Explotaci\u00f3n del CMBD [consultado 1 Jul 2013]. Disponible en: http:\/\/pestadistico.inteligenciadegestion.msssi.es\/"},{"key":"10.1016\/j.aprim.2014.11.002_bib0125","unstructured":"Gisbert R, Brosa M. Base de Datos de Costes Sanitarios eSalud. Barcelona, 2013 [consultado 1 Jul 2013]. Disponible en: http:\/\/www.oblikue.com"},{"key":"10.1016\/j.aprim.2014.11.002_bib0130","first-page":"3","article-title":"An\u00e1lisis de coste efectividad del uso de dronedarona a largo plazo en el tratamiento de la fibrilaci\u00f3n auricular en Espa\u00f1a","volume":"10","author":"Moreno","year":"2011","journal-title":"Rev Esp Econ Salud."},{"key":"10.1016\/j.aprim.2014.11.002_bib0135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.33588\/rn.4309.2005830","article-title":"Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectivo con seguimiento a 3 a\u00f1os","volume":"43","author":"Herv\u00e1s-Angulo","year":"2006","journal-title":"Rev Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.aprim.2014.11.002_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1463-1326.2008.00886.x","article-title":"Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy","volume":"10","author":"Schwarz","year":"2008","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2014.11.002_bib0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3111\/13696990903336597","article-title":"Costs of managing severe hypoglycaemia in three European countries","volume":"12","author":"Hammer","year":"2009","journal-title":"J Med Econ."},{"key":"10.1016\/j.aprim.2014.11.002_bib0150","unstructured":"World Health Organization. ATC\/DDD Index WHO Collaborating Centre of Drug Statistics Methodology. 2013 [consultado 1 Jul 2013]. Disponible en: http:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"10.1016\/j.aprim.2014.11.002_bib0155","unstructured":"Consejo General del Colegio Oficial de Farmac\u00e9uticos [consultado 1 Jul 2013]. Disponible en: http:\/\/www.portalfarma.com"},{"key":"10.1016\/j.aprim.2014.11.002_bib0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1258\/jhsrp.2008.007140","article-title":"Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care","volume":"13","author":"Counterweight Project Team","year":"2008","journal-title":"J Health Serv Res Policy."},{"key":"10.1016\/j.aprim.2014.11.002_bib0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit."},{"key":"10.1016\/j.aprim.2014.11.002_bib0170","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open."},{"key":"10.1016\/j.aprim.2014.11.002_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40261-013-0155-0","article-title":"Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands","volume":"34","author":"Van Haalen","year":"2014","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.aprim.2014.11.002_bib0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1464-5491.2003.00972.x","article-title":"The impact of diabetes-related complications on healthcare costs: Results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)","volume":"20","author":"Clarke","year":"2003","journal-title":"Diabet Med."},{"key":"10.1016\/j.aprim.2014.11.002_bib0185","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination \u2014 dapagliflozin in combination therapy for treating type 2 diabetes. Issue date: May 2013 [consultado 1 Jul 2013]. Disponible en: http:\/\/www.nice.org.uk\/nicemedia\/live\/13722\/63966\/63966.pdf"}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656714003904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656714003904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:46:36Z","timestamp":1747331196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656714003904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0212656714003904"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2014.11.002","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An\u00e1lisis de coste-efectividad de dapagliflozina en comparaci\u00f3n con los inhibidores de la DPP4 y otros antidiab\u00e9ticos orales en el tratamiento de la diabetes mellitus tipo 2 en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}